Control Bionics' Exclusive Distribution Agreement with Smart Box Ltd

Control Bionics Limited (ASX:CBL) has entered into an exclusive distribution agreement with Smart Box Ltd, a leading provider of assistive technology in the UK, for the sale of its innovative NeuroNode® device into the United Kingdom and Ireland. This strategic partnership aims to expand the availability of the ground-breaking NeuroNode® technology to individuals with conditions such as Motor Neurone Disease (MND), cerebral palsy, and other neurological disorders that impair communication and motor function.

Executive Commentary on UK and Ireland Distribution Agreement

Jeremy Steele, CEO of Control Bionics, expressed, 'We are thrilled to partner with Smart Box to bring NeuroNode® to the UK and Irish market. This exclusive agreement marks an exciting step in our mission to empower people with severe disabilities to communicate and regain control of their lives through innovative technology.' Steele added, 'By leveraging Smart Box's expertise and established network, we are confident that this partnership will accelerate the adoption of NeuroNode® across the UK and Ireland and improve the quality of life for countless individuals with speech and motor impairments.'

Summary of Control Bionics' Distribution Agreement and Outlook

Control Bionics (ASX:CBL) has expanded its global reach by securing an exclusive distribution agreement with Smart Box Ltd for the sale of its NeuroNode® device in the UK and Ireland. This strategic partnership aims to provide individuals with conditions such as Motor Neurone Disease (MND), cerebral palsy, and other neurological disorders access to innovative communication technology. The agreement highlights the company's commitment to rapidly grow its 'NeuroNode® Only' business and strengthen its presence in the European market. With more than 1,200 people diagnosed with MND and up to 2,000 diagnosed with Cerebral Palsy each year in the UK and Ireland, Control Bionics aims to address the needs of these individuals through this exclusive distribution agreement. The company's CEO, Jeremy Steele, expressed confidence in the partnership's potential to enhance the lives of users across these countries and accelerate the adoption of NeuroNode® technology. Control Bionics' expansion into the European market signifies a significant step towards achieving its mission of empowering individuals with severe disabilities to communicate and improve their quality of life through innovative assistive technology.